Atopic Dermatitis is the most prevalent type of eczema. The drug we developed to treat the inflammation and itch associated with the disease is currently being tested in human clinical trials.
UC is a chronic disease with no cure. Our work focuses on discovering safer and more effective small-molecule treatments, and we have identified and validated a novel AI-generated target with no previous link to UC.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and ultimately fatal lung disease. Our collaboration with AstraZeneca uses AI to interrogate vast amounts of data and uncover novel targets for IPF.
GBM is a complex, aggressive and lethal brain tumour. Our work focuses on mechanisms that may contribute to the progression and relapse of the disease, and we advanced one of the most promising candidates through to lead optimisation.
Amyotrophic Lateral Sclerosis
ALS is a progressive and ultimately fatal neurodegenerative disease. Our two programmes aim to identify targets to treat ALS, and we have progressed two targets to candidate seeking and lead optimization.
We used our Platform to uncover baricitinib - an approved arthritis drug - as a potential COVID-19 treatment. Our novel hypothesis was validated in global clinical trials and baricitinib is now approved for emergency use in the US, Japan and India.
Chronic Kidney Disease
CKD is characterised by a gradual loss of kidney function. We partnered with AstraZeneca to discover novel targets for CKD and so far, we have delivered the first novel AI-generated target to AstraZeneca’s drug portfolio.